PHILADELPHIA, PA – The global type 1 diabetes (T1D) community reached a historic milestone this week as Breakthrough T1D (formerly JDRF) concluded its inaugural Clinical & Research Congress (CRC 2026). Held in the heart of Philadelphia, the three-day summit represented the first-ever large-scale gathering focused exclusively on T1D, uniting more than a thousand researchers, clinicians, industry pioneers, and patient advocates.
n
The congress served as a rigorous platform for sharing breakthroughs in disease-modifying therapies, islet cell replacement, and advanced screening technologies. As the organization transitions into its new identity as "Breakthrough T1D," the event signaled a definitive shift from managing a chronic condition to actively pursuing its prevention and biological cure.
n
Main Facts: A Unified Front Against T1D
n
The CRC 2026 was designed to bridge the gap between laboratory research and bedside clinical application. For decades, T1D research has been presented at broader endocrinology conferences where it often competed for attention with type 2 diabetes. By creating a dedicated space, Breakthrough T1D has fostered a concentrated environment for "translational medicine"—the process of turning scientific discoveries into practical treatments.
n
Key themes of the congress included:
n
- n
- The Rise of Islet Cell Therapy: Moving toward "functional cures" through cell replacement.
- Disease-Modifying Therapies (DMTs): Shifting the focus from insulin replacement to altering the immune system’s attack on insulin-producing cells.
- Universal Screening: The push for population-wide testing for T1D autoantibodies to prevent Diabetic Ketoacidosis (DKA) and identify candidates for early intervention.
- Technological Integration: Improving the "clinical adoption" of Automated Insulin Delivery (AID) systems to ensure that life-saving technology reaches all socioeconomic groups.
n
n
n
n
n
Chronology of the Congress: Three Days of Discovery
n
Day 1: The Biology of Replacement and the Logic of Delivery
n
The opening day focused on the physical mechanisms of the disease and the current gold standard of care. The morning sessions were dominated by updates on islet cell therapy. Unlike traditional organ transplants, islet cell transplantation involves infusing insulin-producing cells into the liver or other sites. Researchers shared data from ongoing clinical trials exploring stem-cell-derived islets, which promise to solve the "supply problem" that has historically limited transplantation to a few select patients.
n
The afternoon pivoted to Automated Insulin Delivery (AID) systems. While the technology (often called the "artificial pancreas") has advanced rapidly, the conference highlighted a significant "adoption gap." Clinicians discussed the barriers that prevent patients from accessing these systems, including insurance hurdles and the need for better professional training for healthcare providers (HCPs) in non-specialized clinics.
n
Day 2: Modification, Detection, and the Human Element
n
Day 2 shifted the focus from replacing insulin to stopping the disease in its tracks. The spotlight was on Disease-Modifying Therapies (DMTs). Following the FDA approval of the first-ever DMT to delay the onset of T1D (Teplizumab), the congress explored the "next generation" of immunotherapies. These drugs aim to "re-educate" the immune system to stop attacking beta cells without compromising the patient’s overall ability to fight infections.
n
Equally important was the session on "Early Detection." Experts argued that T1D should no longer be diagnosed only when symptoms appear, as 80% of beta cell mass is often gone by that point. Instead, they advocated for screening programs that identify the disease in "Stage 1" or "Stage 2"—before insulin is even required.
n
The day concluded with a powerful session on the "Lived Experience." Patient advocates reminded the scientific community that while data points are vital, the daily mental burden of T1D—ranging from "diabetes burnout" to the constant fear of hypoglycemia—remains a critical metric for success.
n
Day 3: The Future of Screening and the "Cure" Debate
n
The final day addressed the logistical and ethical frameworks required to bring these breakthroughs to the masses. Discussions centered on "Centers of Reference"—specialized hubs that standardize T1D care across different regions to ensure that a patient in a rural area receives the same quality of care as one in a major metropolitan center.
n
A highlight of the closing day was the spirited debate regarding the merits of Islet Cell Therapy versus Disease-Modifying Therapies. While islet therapy offers a potential "functional cure" for those who already have the disease, DMTs offer the hope of preventing the disease entirely in future generations. The consensus was clear: the T1D community requires a "both/and" approach rather than "either/or."
n
Supporting Data: The Magnitude of the Challenge
n
The urgency of the CRC 2026 is underscored by the rising global prevalence of type 1 diabetes. According to data presented during the congress:
n
- n
- Global Impact: There are currently over 8.7 million people living with T1D worldwide, with the number expected to rise to over 13 million by 2040.
- The Screening Gap: Currently, less than 10% of people diagnosed with T1D are identified through screening; the vast majority are diagnosed only after presenting with life-threatening DKA.
- Economic Burden: In the United States alone, the annual economic cost of T1D (including medical expenses and lost productivity) exceeds $14 billion.
- Clinical Success: Data from recent stem-cell-derived islet trials (such as those by Vertex Pharmaceuticals) showed that several participants achieved "insulin independence," a feat thought nearly impossible a decade ago.
n
n
n
n
Official Responses: A Call to Action
The leadership of Breakthrough T1D emphasized that the congress was not just an academic exercise but a catalyst for systemic change.
"This congress marks a turning point," stated a spokesperson for Breakthrough T1D. "For the first time, we have the entire ecosystem—from the scientist at the bench to the clinician in the office and the person living with the disease—all in one room with a singular focus on T1D. We are no longer just hoping for a cure; we are mapping the specific clinical pathways to deliver it."
Dr. Sandy Vogt, a lead contributor to the congress recap, noted the importance of the multidisciplinary approach. "The diversity of expertise here in Philadelphia has been staggering. By bringing together experts in immunology, medical devices, and psychology, we are addressing the disease as a whole-person issue, not just a blood sugar issue."
Sponsors and donors also voiced their commitment, noting that the inaugural success of CRC 2026 has set a high bar for future investment in T1D-specific research.
Implications: What This Means for the T1D Community
The conclusions drawn at CRC 2026 have profound implications for patients and the healthcare system at large.
1. From "Management" to "Disease Interruption"
The most significant takeaway is that the medical community is moving away from a "reactive" model of care. With the advancement of DMTs and universal screening, T1D is beginning to be treated like other autoimmune conditions where early intervention can significantly alter the disease trajectory. This could mean that future generations of children at risk for T1D may never need to start insulin.
2. The Democratization of Technology
The focus on "clinical adoption" suggests a move toward making high-tech care the baseline, not the exception. By addressing the "stigma" associated with diabetes and the barriers to technology, the congress laid the groundwork for a more equitable healthcare landscape where a patient’s zip code does not determine their A1c.
3. Standardized Care Models
The proposal for "Centers of Reference" suggests that the T1D community is moving toward a more structured global network. This would allow for faster rollout of new therapies, as clinical trial results can be disseminated and implemented across a standardized network of clinics more efficiently.
4. Redefining the "Cure"
The congress helped refine what a "cure" looks like. While a biological cure (full restoration of insulin production without immunosuppression) remains the ultimate goal, the "functional cure" (islet cells that require minimal intervention) and the "technological cure" (fully closed-loop AID systems) are now tangible realities for many.
Looking Ahead: CRC 2027
As the delegates departed Philadelphia, the momentum was palpable. Breakthrough T1D has already announced that the second annual Clinical & Research Congress will take place in Washington, D.C., from October 15-17, 2027.
The move to the nation’s capital is strategic, signaling an increased focus on the "advocacy" pillar discussed on Day 2. By holding the next congress in D.C., the organization aims to bring the latest scientific breakthroughs directly to the doorstep of policymakers, ensuring that the legislative and insurance frameworks evolve as quickly as the science itself.
For the millions of people living with type 1 diabetes, CRC 2026 was more than a conference; it was a declaration that the era of simply "managing" T1D is coming to an end, and the era of "breaking through" has begun.
